RECURRENT MYCOSIS FUNGOIDES
Clinical trials for RECURRENT MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for RECURRENT MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have come back or not responded to treatment. The main goals are to find the best dose and check for side effects. The drug works by helping the immune system attack cance…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy offers hope for patients with relapsed T-Cell lymphoma
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (a drug that blocks enzymes cancer cells need to grow), in people with peripheral T-cell lymphoma that has come back or stopped responding to tr…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Experimental combo targets Hard-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose, check safety, and see if the combination shrinks tumors. About 38 adults with certai…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC